GLYCYX MOR, INC.

Biotech · Private

Axelopran, a peripherally-restricted opioid antagonist designed to enhance immune checkpoint inhibitor efficacy in cancer patients receiving concurrent opioid analgesia.

Grants
$1.2M
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)$1,197,275
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1962Humanity Inc.—$2.4M
1963Verastem Oncology——
1964VIRONGY BIOSCIENCES, INC.——
1965GLYCYX MOR, INC.——
1966ARMR Sciences Inc.—$30M
1967AOBiome LLC—$3.7M
1968Mersana Therapeutics—$69M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Methods Of Treating Cancer And Other Conditions With A Mu Opioid Receptor Antagonistapplication
  • Methods, Systems, And Compositions Related To Use Of Mu Opioid Receptor (mor) Antagonistsapplication
  • Methods Of Treating Cancer And Other Conditions With A Mu Opioid Receptor Antagonistapplication
  • Methods Of Treating Cancer And Other Conditions With A Mu Opioid Receptor Antagonistapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.